Italia markets close in 45 minutes

FTSE MIB
33.549,37
-157,84(-0,47%)
Dow Jones
38.983,17
-128,99(-0,33%)
Nasdaq
17.759,29
+41,64(+0,24%)
Nikkei 225
39.667,07
+493,92(+1,26%)
Petrolio
80,68
-0,15(-0,19%)
Bitcoin EUR
57.661,71
-279,12(-0,48%)

NBIX Jul 2024 130.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

8,38

0,00

(0,00%)

In data: 10:48AM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat